Wegovy 2.4mg: the maintenance dose explained

How does a patient actually get to 2.4mg, and what happens there?

Wegovy's dosing ladder exists for a reason. Starting at the lowest strength keeps gastrointestinal side effects manageable while the body adjusts. The licensed titration schedule runs 0.25mg for four weeks, then 0.5mg, then 1.0mg, then 1.7mg, with 2.4mg reached at roughly week 17, give or take, depending on how well each step is tolerated. Your prescriber decides whether to hold at a step longer if side effects need more time to settle.

At 2.4mg, the appetite-reducing effect of semaglutide tends to be at its most pronounced. The medicine acts on GLP-1 receptors, slowing gastric emptying and signalling fullness to the brain, so meals feel satisfying sooner and hunger between them drops. Most people find this is where the weight-loss trajectory becomes most noticeable. It does not mean 2.4mg is the right long-term dose for everyone (some patients do well maintaining on 1.7mg) but it is the dose at which the STEP 1 trial demonstrated its headline results. Our semaglutide overview covers the mechanism in more detail if the science interests you.

One practical point worth flagging early: keeping the pen in the fridge door rather than the back of the shelf makes the weekly routine easier to remember, and the pen stays at the right temperature. The Patient Information Leaflet, as noted on the NHS semaglutide page, is the definitive guide to storage windows and what to do if a pen has been out of the fridge for longer than recommended.

What did the clinical trial evidence actually show at 2.4mg?

The primary evidence base for Wegovy 2.4mg is the STEP programme. STEP 1, published in the New England Journal of Medicine, randomised adults with obesity but without type 2 diabetes to semaglutide 2.4mg weekly or placebo for 68 weeks, alongside reduced-calorie diet and increased activity. Participants in the semaglutide group lost an average of around 15% of their body weight, compared with roughly 2.4% in the placebo group. Around one in three participants lost 20% or more.

Those are meaningful numbers, but they come with honest caveats. Trial populations follow structured protocols, receive regular support, and tend to be highly motivated. Real-world results vary. The figures also reflect 68 weeks of continuous treatment; weight tends to return when the medicine is stopped, because semaglutide manages the biology of appetite rather than permanently resetting it.

NICE recommended semaglutide for weight management (guidance TA875) on specific criteria, including use within a specialist weight management service for up to two years. The full eligibility conditions and NHS access picture are covered on our Wegovy treatment page. For context on how 2.4mg compares with the newer 7.2mg option, the Wegovy 7.2mg page sets out what changed and what the approval means in practice.

What side effects are most common at the 2.4mg maintenance dose?

The side-effect profile at 2.4mg is broadly the same as at earlier doses but can be more noticeable when moving up from 1.7mg. Nausea is the most frequently reported; others include vomiting, diarrhoea, constipation, indigestion, and fatigue. These tend to be most intense in the first week or two after a dose increase and usually ease as the body adjusts, though they do not disappear entirely for everyone.

Serious side effects are less common but important to know about. The MHRA has highlighted acute pancreatitis as a known, infrequent risk across GLP-1 medicines: severe, persistent abdominal pain that may spread to the back, with or without vomiting, warrants urgent medical attention. Gallbladder problems and dehydration from persistent vomiting or diarrhoea are also worth watching for.

Patients can report any suspected side effects (including unexpected ones) through the MHRA's Yellow Card scheme. This is especially valuable for newer medicines that are still accumulating post-market safety data. Wegovy carries a Black Triangle (▼) symbol indicating it is subject to additional monitoring. If you are unsure whether a symptom needs urgent attention or just patience, the Patient Information Leaflet and your prescriber are the right first stops, not a forum.

Is 2.4mg still the highest dose you can get on Wegovy?

No. The MHRA approved a 7.2mg maintenance dose in January 2026, and a dedicated single-dose 7.2mg pen followed in April 2026. That pen is authorised for adults with a BMI of 30 or above, and the titration still starts from 0.25mg, patients do not jump straight to the higher dose. Early data suggest around 20.7% average weight loss over 72 weeks at 7.2mg, which narrows the gap with tirzepatide (Mounjaro) seen in the SURMOUNT-5 head-to-head trial.

Whether 7.2mg is appropriate is a clinical decision. Some people maintain well at 2.4mg with an acceptable side-effect profile and see no reason to go further. Others may benefit from the additional effect. Neither scenario is better in the abstract, they depend on individual response, tolerability, and clinical judgement. The question of cost across doses is also a real consideration; higher doses tend to carry a higher price, and it is worth understanding what is included in any quoted price before committing.

If you are currently on 2.4mg and wondering whether to continue, move to a higher dose, or explore an alternative, speaking to a prescriber is the right move. Some patients also find it helpful to read about what to expect on day four of a new Wegovy dose, particularly when adjusting to a step up. At nume, a named clinician reads every consultation (not software) and can work through the specifics of your situation. You can also read about the range of weight-loss treatments we review, or check our frequently asked questions if there is something straightforward you want answered first.